{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:31:22Z","timestamp":1766579482689,"version":"3.40.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01292-0","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:45:54Z","timestamp":1742489154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-\u03b1 Modulators and Fibrates on Microvascular Disease: Is There Still Room?"],"prefix":"10.1007","volume":"27","author":[{"given":"Lucas Lage","family":"Marinho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matheus Laterza","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Iatan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Colombo","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana Hanna","family":"Rached","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul Cavalcante","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"6","key":"1292_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1089\/jwh.2019.7826","volume":"29","author":"H Patel","year":"2020","unstructured":"Patel H, Aggarwal NT, Rao A, Bryant E, Sanghani RM, Byrnes M, et al. Microvascular disease and Small-Vessel disease: the nexus of multiple diseases of women. J Womens Health (Larchmt). 2020;29(6):770\u20139. https:\/\/doi.org\/10.1089\/jwh.2019.7826.","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"1292_CR2","doi-asserted-by":"publisher","first-page":"e011104","DOI":"10.1161\/JAHA.118.011104","volume":"8","author":"C Berry","year":"2019","unstructured":"Berry C, Sidik N, Pereira AC, Ford TJ, Touyz RM, Kaski JC, et al. Small-Vessel disease in the heart and brain: current knowledge, unmet therapeutic need, and future directions. J Am Heart Assoc. 2019;8(3):e011104. https:\/\/doi.org\/10.1161\/JAHA.118.011104.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1292_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12933-023-02056-3","volume":"22","author":"D Mauricio","year":"2023","unstructured":"Mauricio D, Gratacos M, Franch-Nadal J. Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves. Cardiovasc Diabetol. 2023;22(1):314. https:\/\/doi.org\/10.1186\/s12933-023-02056-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"14","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"C Diabetes","year":"1993","unstructured":"Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386. https:\/\/doi.org\/10.1056\/NEJM199309303291401.","journal-title":"N Engl J Med"},{"issue":"9","key":"1292_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2337\/diab.39.9.1116","volume":"39","author":"TJ Orchard","year":"1990","unstructured":"Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. Diabetes. 1990;39(9):1116\u201324. https:\/\/doi.org\/10.2337\/diab.39.9.1116.","journal-title":"Diabetes"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"61038","DOI":"10.1155\/2007\/61038","volume":"2007","author":"M Lorenzi","year":"2007","unstructured":"Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007:61038. https:\/\/doi.org\/10.1155\/2007\/61038.","journal-title":"Exp Diabetes Res"},{"issue":"9","key":"1292_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.223545.","journal-title":"Circ Res"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"343560","DOI":"10.1155\/2013\/343560","volume":"2013","author":"JM Tarr","year":"2013","unstructured":"Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560. https:\/\/doi.org\/10.1155\/2013\/343560.","journal-title":"ISRN Ophthalmol"},{"issue":"4","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1172\/JCI17862","volume":"111","author":"EL Feldman","year":"2003","unstructured":"Feldman EL. Oxidative stress and diabetic neuropathy: a new Understanding of an old problem. J Clin Invest. 2003;111(4):431\u20133. https:\/\/doi.org\/10.1172\/JCI17862.","journal-title":"J Clin Invest"},{"issue":"20","key":"1292_CR10","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1001\/jama.288.20.2579","volume":"288","author":"MJ Sheetz","year":"2002","unstructured":"Sheetz MJ, King GL. Molecular Understanding of hyperglycemia\u2019s adverse effects for diabetic complications. JAMA. 2002;288(20):2579\u201388. https:\/\/doi.org\/10.1001\/jama.288.20.2579.","journal-title":"JAMA"},{"issue":"6","key":"1292_CR11","first-page":"2887","volume":"35","author":"AK Kumagai","year":"1994","unstructured":"Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. Invest Ophthalmol Vis Sci. 1994;35(6):2887\u201394.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1292_CR12","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1523\/JNEUROSCI.10-12-03862.1990","volume":"10","author":"SI Harik","year":"1990","unstructured":"Harik SI, Kalaria RN, Andersson L, Lundahl P, Perry G. Immunocytochemical localization of the erythroid glucose transporter: abundance in tissues with barrier functions. J Neurosci. 1990;10(12):3862\u201372. https:\/\/doi.org\/10.1523\/JNEUROSCI.10-12-03862.1990.","journal-title":"J Neurosci"},{"issue":"5","key":"1292_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1679\/aohc.62.459","volume":"62","author":"N Tserentsoodol","year":"1999","unstructured":"Tserentsoodol N, Shin BC, Koyama H, Suzuki T, Takata K. Immunolocalization of tight junction proteins, occludin and ZO-1, and glucose transporter GLUT1 in the cells of the blood-nerve barrier. Arch Histol Cytol. 1999;62(5):459\u201369. https:\/\/doi.org\/10.1679\/aohc.62.459.","journal-title":"Arch Histol Cytol"},{"key":"1292_CR14","doi-asserted-by":"publisher","unstructured":"Heilig CW, Brosius FC 3rd, Cunningham C. Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Mol Med. 2006;8(4):1\u201318. https:\/\/doi.org\/10.1017\/S1462399406010490.","DOI":"10.1017\/S1462399406010490"},{"key":"1292_CR15","unstructured":"International Diabetes Federation. IDF: Diabetes Atlas, 10th edn. Brussels, Belgium. 2021. https:\/\/www.diabetesatlas.org Accessed 1st October 2024."},{"issue":"3","key":"1292_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364. https:\/\/doi.org\/10.2337\/dc11-1909.","journal-title":"Diabetes Care"},{"issue":"11","key":"1292_CR17","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and Meta-analysis. Ophthalmology. 2021;128(11):1580\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027.","journal-title":"Ophthalmology"},{"key":"1292_CR18","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States. 2023. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2023."},{"issue":"1","key":"1292_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/dc20-1913","volume":"44","author":"HT Cheng","year":"2021","unstructured":"Cheng HT, Xu X, Lim PS, Hung KY. Worldwide epidemiology of Diabetes-Related End-Stage renal disease, 2000\u20132015. Diabetes Care. 2021;44(1):89\u201397. https:\/\/doi.org\/10.2337\/dc20-1913.","journal-title":"Diabetes Care"},{"issue":"10","key":"1292_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","volume":"19","author":"CW Hicks","year":"2019","unstructured":"Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86. https:\/\/doi.org\/10.1007\/s11892-019-1212-8.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"1292_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-021-01290-x","volume":"20","author":"R de Ritter","year":"2021","unstructured":"de Ritter R, Sep SJS, van der Kallen CJH, van Greevenbroek MMJ, de Jong M, Vos RC, et al. Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: the Maastricht study. Cardiovasc Diabetol. 2021;20(1):102. https:\/\/doi.org\/10.1186\/s12933-021-01290-x.","journal-title":"Cardiovasc Diabetol"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ahj.2021.10.181","volume":"243","author":"SV Arnold","year":"2022","unstructured":"Arnold SV, Khunti K, Tang F, Chen H, Cid-Ruzafa J, Cooper A, et al. Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: results from the longitudinal global discover study. Am Heart J. 2022;243:232\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2021.10.181.","journal-title":"Am Heart J"},{"issue":"6","key":"1292_CR23","doi-asserted-by":"publisher","first-page":"e0000599","DOI":"10.1371\/journal.pgph.0000599","volume":"2","author":"F Aikaeli","year":"2022","unstructured":"Aikaeli F, Njim T, Gissing S, Moyo F, Alam U, Mfinanga SG, et al. Prevalence of microvascular and macrovascular complications of diabetes in newly diagnosed type 2 diabetes in low-and-middle-income countries: A systematic review and meta-analysis. PLOS Glob Public Health. 2022;2(6):e0000599. https:\/\/doi.org\/10.1371\/journal.pgph.0000599.","journal-title":"PLOS Glob Public Health"},{"issue":"9","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2337\/diacare.28.9.2280","volume":"28","author":"LC Lanting","year":"2005","unstructured":"Lanting LC, Joung IM, Mackenbach JP, Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care. 2005;28(9):2280\u20138. https:\/\/doi.org\/10.2337\/diacare.28.9.2280.","journal-title":"Diabetes Care"},{"issue":"19","key":"1292_CR25","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1001\/jama.287.19.2519","volume":"287","author":"AJ Karter","year":"2002","unstructured":"Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519\u201327. https:\/\/doi.org\/10.1001\/jama.287.19.2519.","journal-title":"JAMA"},{"issue":"9131","key":"1292_CR26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"Intensive blood-glucose","year":"1998","unstructured":"Intensive blood-glucose. Control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"key":"1292_CR27","doi-asserted-by":"publisher","unstructured":"An J, Nichols GA, Qian L, Munis MA, Harrison TN, Li Z, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9(1). https:\/\/doi.org\/10.1136\/bmjdrc-2020-001847.","DOI":"10.1136\/bmjdrc-2020-001847"},{"issue":"1","key":"1292_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-018-0787-8","volume":"17","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150. https:\/\/doi.org\/10.1186\/s12933-018-0787-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1292_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/01.hyp.19.5.403","volume":"19","author":"M Epstein","year":"1992","unstructured":"Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403\u201318. https:\/\/doi.org\/10.1161\/01.hyp.19.5.403.","journal-title":"Hypertension"},{"issue":"6","key":"1292_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/(SICI)1096-9136(199606)13:6<536::AID-DIA110>3.0.CO;2-J","volume":"13","author":"I Muhlhauser","year":"1996","unstructured":"Muhlhauser I, Bender R, Bott U, Jorgens V, Grusser M, Wagener W, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med. 1996;13(6):536\u201343. https:\/\/doi.org\/10.1002\/(SICI)1096-9136(199606)13:6%3C536::AID-DIA110%3E3.0.CO;2-J.","journal-title":"Diabet Med"},{"issue":"3","key":"1292_CR31","first-page":"146","volume":"48","author":"G Biesenbach","year":"1997","unstructured":"Biesenbach G, Grafinger P, Janko O, Zazgornik J. Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol. 1997;48(3):146\u201350.","journal-title":"Clin Nephrol"},{"issue":"1","key":"1292_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdiacomp.2017.09.010","volume":"32","author":"A Gedebjerg","year":"2018","unstructured":"Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications. 2018;32(1):34\u201340. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.09.010.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"1292_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1167\/iovs.02-0648","volume":"45","author":"TJ Lyons","year":"2004","unstructured":"Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT\/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45(3):910\u20138. https:\/\/doi.org\/10.1167\/iovs.02-0648.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1292_CR34","doi-asserted-by":"publisher","unstructured":"Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early treatment diabetic retinopathy study (ETDRS) report 22. Arch Ophthalmol. 1996;114(9):1079\u201384. https:\/\/doi.org\/10.1001\/archopht.1996.01100140281004.","DOI":"10.1001\/archopht.1996.01100140281004"},{"issue":"11","key":"1292_CR35","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","volume":"74","author":"F Emanuelsson","year":"2019","unstructured":"Emanuelsson F, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Impact of LDL cholesterol on microvascular versus macrovascular disease: A Mendelian randomization study. J Am Coll Cardiol. 2019;74(11):1465\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.037.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1292_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s1262-3636(07)70088-5","volume":"30","author":"S Hadjadj","year":"2004","unstructured":"Hadjadj S, Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab. 2004;30(1):43\u201351. https:\/\/doi.org\/10.1016\/s1262-3636(07)70088-5.","journal-title":"Diabetes Metab"},{"issue":"9","key":"1292_CR37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","volume":"129","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999\u20131008. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002529.","journal-title":"Circulation"},{"issue":"6","key":"1292_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580\u201391. https:\/\/doi.org\/10.1056\/NEJMoa0706245.","journal-title":"N Engl J Med"},{"issue":"4","key":"1292_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jacc.2024.05.028","volume":"84","author":"LL Marinho","year":"2024","unstructured":"Marinho LL, Everett BM, Aday AW, Visseren FLJ, MacFadyen JG, Zaharris E, et al. Effect of pemafibrate on diabetic foot ulceration and gangrene: an exploratory analysis from PROMINENT. J Am Coll Cardiol. 2024;84(4):408\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.028.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1292_CR40","doi-asserted-by":"publisher","first-page":"EVIDoa2400179","DOI":"10.1056\/EVIDoa2400179","volume":"3","author":"D Preiss","year":"2024","unstructured":"Preiss D, Logue J, Sammons E, Zayed M, Emberson J, Wade R, et al. Effect of Fenofibrate on progression of diabetic retinopathy. NEJM Evid. 2024;3(8):EVIDoa2400179. https:\/\/doi.org\/10.1056\/EVIDoa2400179.","journal-title":"NEJM Evid"},{"issue":"5","key":"1292_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","volume":"30","author":"F Lalloyer","year":"2010","unstructured":"Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30(5):894\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.108.179689.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6294","key":"1292_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347(6294):645\u201350. https:\/\/doi.org\/10.1038\/347645a0.","journal-title":"Nature"},{"issue":"5","key":"1292_CR43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","volume":"37","author":"K Schoonjans","year":"1996","unstructured":"Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37(5):907\u201325.","journal-title":"J Lipid Res"},{"issue":"1","key":"1292_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","volume":"23","author":"JC Fruchart","year":"2021","unstructured":"Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T. Selective peroxisome Proliferator-Activated receptor alpha modulators (SPPARMalpha) in the metabolic syndrome: is pemafibrate light at the end of the tunnel?? Curr Atheroscler Rep. 2021;23(1):3. https:\/\/doi.org\/10.1007\/s11883-020-00897-x.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1292_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI27989","volume":"116","author":"P Lefebvre","year":"2006","unstructured":"Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116(3):571\u201380. https:\/\/doi.org\/10.1172\/JCI27989.","journal-title":"J Clin Invest"},{"issue":"1","key":"1292_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential: A consensus statement from the international atherosclerosis society (IAS) and the residual risk reduction initiative (R3i) foundation. Cardiovasc Diabetol. 2019;18(1):71. https:\/\/doi.org\/10.1186\/s12933-019-0864-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1292_CR47","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","volume":"115","author":"JD Brown","year":"2007","unstructured":"Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.475673.","journal-title":"Circulation"},{"issue":"1","key":"1292_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1):124. https:\/\/doi.org\/10.1186\/s12933-017-0602-y.","journal-title":"Cardiovasc Diabetol"},{"key":"1292_CR49","doi-asserted-by":"publisher","unstructured":"Davies BS, Beigneux AP, Barnes RH 2nd, Tu Y, Gin P, Weinstein MM, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 2010;12(1):42\u201352. https:\/\/doi.org\/10.1016\/j.cmet.2010.04.016.","DOI":"10.1016\/j.cmet.2010.04.016"},{"issue":"36","key":"1292_CR50","doi-asserted-by":"publisher","first-page":"e2211136119","DOI":"10.1073\/pnas.2211136119","volume":"119","author":"SG Young","year":"2022","unstructured":"Young SG, Song W, Yang Y, Birrane G, Jiang H, Beigneux AP, et al. A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism. Proc Natl Acad Sci U S A. 2022;119(36):e2211136119. https:\/\/doi.org\/10.1073\/pnas.2211136119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1292_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/ATVBAHA.108.178756","volume":"30","author":"RJ Havel","year":"2010","unstructured":"Havel RJ. Triglyceride-rich lipoproteins and plasma lipid transport. Arterioscler Thromb Vasc Biol. 2010;30(1):9\u201319. https:\/\/doi.org\/10.1161\/ATVBAHA.108.178756.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1292_CR52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.cmet.2014.01.017","volume":"19","author":"CN Goulbourne","year":"2014","unstructured":"Goulbourne CN, Gin P, Tatar A, Nobumori C, Hoenger A, Jiang H, et al. The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab. 2014;19(5):849\u201360. https:\/\/doi.org\/10.1016\/j.cmet.2014.01.017.","journal-title":"Cell Metab"},{"issue":"1","key":"1292_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2019.05.023","volume":"30","author":"SG Young","year":"2019","unstructured":"Young SG, Fong LG, Beigneux AP, Allan CM, He C, Jiang H, et al. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab. 2019;30(1):51\u201365. https:\/\/doi.org\/10.1016\/j.cmet.2019.05.023.","journal-title":"Cell Metab"},{"issue":"Pt 3","key":"1292_CR54","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1042\/BST0350472","volume":"35","author":"F Karpe","year":"2007","unstructured":"Karpe F, Bickerton AS, Hodson L, Fielding BA, Tan GD, Frayn KN. Removal of triacylglycerols from chylomicrons and VLDL by capillary beds: the basis of lipoprotein remnant formation. Biochem Soc Trans. 2007;35(Pt 3):472\u20136. https:\/\/doi.org\/10.1042\/BST0350472.","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"1292_CR55","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1073\/pnas.0538015100","volume":"100","author":"O Ziouzenkova","year":"2003","unstructured":"Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003;100(5):2730\u20135. https:\/\/doi.org\/10.1073\/pnas.0538015100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1292_CR56","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nrendo.2010.89","volume":"6","author":"A Hiukka","year":"2010","unstructured":"Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol. 2010;6(8):454\u201363. https:\/\/doi.org\/10.1038\/nrendo.2010.89.","journal-title":"Nat Rev Endocrinol"},{"issue":"38","key":"1292_CR57","doi-asserted-by":"publisher","first-page":"15401","DOI":"10.1073\/pnas.1307211110","volume":"110","author":"Y Hu","year":"2013","unstructured":"Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, et al. Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A. 2013;110(38):15401\u20136. https:\/\/doi.org\/10.1073\/pnas.1307211110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1292_CR58","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2337\/db17-0926","volume":"68","author":"J Yuan","year":"2019","unstructured":"Yuan J, Tan JTM, Rajamani K, Solly EL, King EJ, Lecce L, et al. Fenofibrate rescues Diabetes-Related impairment of Ischemia-Mediated angiogenesis by PPARalpha-Independent modulation of Thioredoxin-Interacting protein. Diabetes. 2019;68(5):1040\u201353. https:\/\/doi.org\/10.2337\/db17-0926.","journal-title":"Diabetes"},{"issue":"6","key":"1292_CR59","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1159\/000479999","volume":"42","author":"Y Deng","year":"2017","unstructured":"Deng Y, Han X, Yao Z, Sun Y, Yu J, Cai J, et al. PPARalpha agonist stimulated angiogenesis by improving endothelial precursor cell function via a NLRP3 inflammasome pathway. Cell Physiol Biochem. 2017;42(6):2255\u201366. https:\/\/doi.org\/10.1159\/000479999.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"1292_CR60","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.1167\/iovs.11-7282","volume":"52","author":"K Trudeau","year":"2011","unstructured":"Trudeau K, Roy S, Guo W, Hernandez C, Villarroel M, Simo R, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci. 2011;52(9):6348\u201354. https:\/\/doi.org\/10.1167\/iovs.11-7282.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"45","key":"1292_CR61","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274(45):32048\u201354. https:\/\/doi.org\/10.1074\/jbc.274.45.32048.","journal-title":"J Biol Chem"},{"issue":"12","key":"1292_CR62","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.2337\/db13-0800","volume":"62","author":"JE Noonan","year":"2013","unstructured":"Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of Fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968\u201375. https:\/\/doi.org\/10.2337\/db13-0800.","journal-title":"Diabetes"},{"issue":"1","key":"1292_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2337\/db11-0413","volume":"62","author":"Y Chen","year":"2013","unstructured":"Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, et al. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261\u201372. https:\/\/doi.org\/10.2337\/db11-0413.","journal-title":"Diabetes"},{"issue":"7","key":"1292_CR64","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1167\/iovs.13-13127","volume":"55","author":"E Moran","year":"2014","unstructured":"Moran E, Ding L, Wang Z, Cheng R, Chen Q, Moore R, et al. Protective and antioxidant effects of PPARalpha in the ischemic retina. Invest Ophthalmol Vis Sci. 2014;55(7):4568\u201376. https:\/\/doi.org\/10.1167\/iovs.13-13127.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1292_CR65","doi-asserted-by":"publisher","unstructured":"Hsu YJ, Lin CW, Cho SL, Yang WS, Yang CM, Yang CH. Protective effect of Fenofibrate on oxidative Stress-Induced apoptosis in Retinal-Choroidal vascular endothelial cells: implication for diabetic retinopathy treatment. Antioxid (Basel). 2020;9(8). https:\/\/doi.org\/10.3390\/antiox9080712.","DOI":"10.3390\/antiox9080712"},{"key":"1292_CR66","doi-asserted-by":"publisher","unstructured":"Tomita Y, Lee D, Miwa Y, Jiang X, Ohta M, Tsubota K, et al. Pemafibrate protects against retinal dysfunction in a murine model of diabetic retinopathy. Int J Mol Sci. 2020;21(17). https:\/\/doi.org\/10.3390\/ijms21176243.","DOI":"10.3390\/ijms21176243"},{"key":"1292_CR67","doi-asserted-by":"publisher","unstructured":"Tomita Y, Ozawa N, Miwa Y, Ishida A, Ohta M, Tsubota K, et al. Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine Oxygen-Induced retinopathy model. Int J Mol Sci. 2019;20(23). https:\/\/doi.org\/10.3390\/ijms20235878.","DOI":"10.3390\/ijms20235878"},{"issue":"2","key":"1292_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/01.cir.103.2.213","volume":"103","author":"N Marx","year":"2001","unstructured":"Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach V, Libby P, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001;103(2):213\u20139. https:\/\/doi.org\/10.1161\/01.cir.103.2.213.","journal-title":"Circulation"},{"issue":"1","key":"1292_CR69","doi-asserted-by":"publisher","first-page":"10837","DOI":"10.1038\/s41598-020-67579-1","volume":"10","author":"A Shiono","year":"2020","unstructured":"Shiono A, Sasaki H, Sekine R, Abe Y, Matsumura Y, Inagaki T, et al. PPARalpha activation directly upregulates thrombomodulin in the diabetic retina. Sci Rep. 2020;10(1):10837. https:\/\/doi.org\/10.1038\/s41598-020-67579-1.","journal-title":"Sci Rep"},{"issue":"6","key":"1292_CR70","doi-asserted-by":"publisher","first-page":"e0235362","DOI":"10.1371\/journal.pone.0235362","volume":"15","author":"H Kawanishi","year":"2020","unstructured":"Kawanishi H, Ohashi K, Ogawa H, Otaka N, Takikawa T, Fang L, et al. A novel selective PPARalpha modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. PLoS ONE. 2020;15(6):e0235362. https:\/\/doi.org\/10.1371\/journal.pone.0235362.","journal-title":"PLoS ONE"},{"issue":"2","key":"1292_CR71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2337\/db20-0635","volume":"70","author":"MA Zayed","year":"2021","unstructured":"Zayed MA, Jin X, Yang C, Belaygorod L, Engel C, Desai K, et al. CEPT1-Mediated phospholipogenesis regulates endothelial cell function and Ischemia-Induced angiogenesis through PPARalpha. Diabetes. 2021;70(2):549\u201361. https:\/\/doi.org\/10.2337\/db20-0635.","journal-title":"Diabetes"},{"issue":"5","key":"1292_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/FJC.0b013e3181bad05d","volume":"54","author":"A Katayama","year":"2009","unstructured":"Katayama A, Yamamoto Y, Tanaka K, Matsubara K, Sugitani M, Fujihara S, et al. Fenofibrate enhances neovascularization in a murine ischemic hindlimb model. J Cardiovasc Pharmacol. 2009;54(5):399\u2013404. https:\/\/doi.org\/10.1097\/FJC.0b013e3181bad05d.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1292_CR73","doi-asserted-by":"publisher","first-page":"e83204","DOI":"10.1371\/journal.pone.0083204","volume":"9","author":"YR Cho","year":"2014","unstructured":"Cho YR, Lim JH, Kim MY, Kim TW, Hong BY, Kim YS, et al. Therapeutic effects of Fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in Db\/db mice. PLoS ONE. 2014;9(1):e83204. https:\/\/doi.org\/10.1371\/journal.pone.0083204.","journal-title":"PLoS ONE"},{"issue":"4","key":"1292_CR74","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2015.03.011","volume":"9","author":"A Othman","year":"2015","unstructured":"Othman A, Benghozi R, Alecu I, Wei Y, Niesor E, von Eckardstein A, et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? J Clin Lipidol. 2015;9(4):568\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2015.03.011.","journal-title":"J Clin Lipidol"},{"key":"1292_CR75","doi-asserted-by":"publisher","unstructured":"Rubsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4). https:\/\/doi.org\/10.3390\/ijms19040942.","DOI":"10.3390\/ijms19040942"},{"issue":"7","key":"1292_CR76","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2337\/diab.17.7.458","volume":"17","author":"LJ Duncan","year":"1968","unstructured":"Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes. 1968;17(7):458\u201367. https:\/\/doi.org\/10.2337\/diab.17.7.458.","journal-title":"Diabetes"},{"issue":"5","key":"1292_CR77","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2337\/diab.18.5.285","volume":"18","author":"BP Harrold","year":"1969","unstructured":"Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of Clofibrate in the treatment of diabetic retinopathy. Diabetes. 1969;18(5):285\u201391. https:\/\/doi.org\/10.2337\/diab.18.5.285.","journal-title":"Diabetes"},{"issue":"9600","key":"1292_CR78","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","volume":"370","author":"AC Keech","year":"2007","unstructured":"Keech AC, Mitchell P, Summanen PA, O\u2019Day J, Davis TM, Moffitt MS, et al. Effect of Fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(07)61607-9.","journal-title":"Lancet"},{"issue":"3","key":"1292_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","volume":"363","author":"AS Group","year":"2010","unstructured":"Group AS, Group AES, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1001288.","journal-title":"N Engl J Med"},{"key":"1292_CR80","doi-asserted-by":"publisher","unstructured":"Action to Control Cardiovascular Risk in Diabetes, Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, et al. Effects of intensive glucose Lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359. https:\/\/doi.org\/10.1056\/NEJMoa0802743.","DOI":"10.1056\/NEJMoa0802743"},{"issue":"Suppl 1","key":"1292_CR81","first-page":"S1","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1\u2013325.","journal-title":"Can J Diabetes"},{"key":"1292_CR82","volume-title":"Diabetes eye health: A guide for health professionals","author":"International Diabetes Federation","year":"2019","unstructured":"International Diabetes Federation. Diabetes eye health: A guide for health professionals. Brussels, Belgium: International Diabetes Federation; 2019."},{"key":"1292_CR83","volume-title":"Management of type 2 diabetes: A handbook for general practice","author":"The Royal Australian College of General Practitioners (RACGP)","year":"2024","unstructured":"The Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP; 2024."},{"issue":"9","key":"1292_CR84","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman SC, Bakris GL. Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care. 2023;46(9):1574\u201386. https:\/\/doi.org\/10.2337\/dci23-0030.","journal-title":"Diabetes Care"},{"issue":"20","key":"1292_CR85","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme Inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456\u201362. https:\/\/doi.org\/10.1056\/NEJM199311113292004.","journal-title":"N Engl J Med"},{"issue":"12","key":"1292_CR86","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360. https:\/\/doi.org\/10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"issue":"12","key":"1292_CR87","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"issue":"24","key":"1292_CR88","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"1292_CR89","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"1292_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"1","key":"1292_CR91","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.hyp.0000044937.95080.e9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone Blockade in patients with diabetic nephropathy. Hypertension. 2003;41(1):64\u20138. https:\/\/doi.org\/10.1161\/01.hyp.0000044937.95080.e9.","journal-title":"Hypertension"},{"issue":"23","key":"1292_CR92","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"6","key":"1292_CR93","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983.","journal-title":"Circulation"},{"issue":"2","key":"1292_CR94","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"3","key":"1292_CR95","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","volume":"45","author":"JC Ansquer","year":"2005","unstructured":"Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, Investigators D. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the diabetes atherosclerosis intervention study (DAIS). Am J Kidney Dis. 2005;45(3):485\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2004.11.004.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1292_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of Fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate intervention and event Lowering in diabetes (FIELD) study. Diabetologia. 2011;54(2):280\u201390. https:\/\/doi.org\/10.1007\/s00125-010-1951-1.","journal-title":"Diabetologia"},{"issue":"1","key":"1292_CR97","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ekir.2018.09.006","volume":"4","author":"R Frazier","year":"2019","unstructured":"Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, et al. Associations of Fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes. Kidney Int Rep. 2019;4(1):94\u2013102. https:\/\/doi.org\/10.1016\/j.ekir.2018.09.006.","journal-title":"Kidney Int Rep"},{"key":"1292_CR98","doi-asserted-by":"publisher","unstructured":"Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. The effect of fibrates on kidney function and chronic kidney disease progression: A systematic review and Meta-Analysis of randomised studies. J Clin Med. 2022;11(3). https:\/\/doi.org\/10.3390\/jcm11030768.","DOI":"10.3390\/jcm11030768"},{"issue":"5","key":"1292_CR99","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/eci.12068","volume":"43","author":"MS Kostapanos","year":"2013","unstructured":"Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43(5):522\u201331. https:\/\/doi.org\/10.1111\/eci.12068.","journal-title":"Eur J Clin Invest"},{"issue":"21","key":"1292_CR100","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"issue":"1","key":"1292_CR101","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-019-0097-9","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. https:\/\/doi.org\/10.1038\/s41572-019-0097-9.","journal-title":"Nat Rev Dis Primers"},{"key":"1292_CR102","doi-asserted-by":"publisher","first-page":"8641942","DOI":"10.1155\/2018\/8641942","volume":"2018","author":"LBL Prabodha","year":"2018","unstructured":"Prabodha LBL, Sirisena ND, Dissanayake VHW. Susceptible and prognostic genetic factors associated with diabetic peripheral neuropathy: A comprehensive literature review. Int J Endocrinol. 2018;2018:8641942. https:\/\/doi.org\/10.1155\/2018\/8641942.","journal-title":"Int J Endocrinol"},{"key":"1292_CR103","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.diabres.2016.08.006","volume":"120","author":"C Politi","year":"2016","unstructured":"Politi C, Ciccacci C, D\u2019Amato C, Novelli G, Borgiani P, Spallone V. Recent advances in exploring the genetic susceptibility to diabetic neuropathy. Diabetes Res Clin Pract. 2016;120:198\u2013208. https:\/\/doi.org\/10.1016\/j.diabres.2016.08.006.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"1292_CR104","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.2337\/dc13-0746","volume":"36","author":"SK Dunnigan","year":"2013","unstructured":"Dunnigan SK, Ebadi H, Breiner A, Katzberg HD, Lovblom LE, Perkins BA, et al. Conduction slowing in diabetic sensorimotor polyneuropathy. Diabetes Care. 2013;36(11):3684\u201390. https:\/\/doi.org\/10.2337\/dc13-0746.","journal-title":"Diabetes Care"},{"issue":"2","key":"1292_CR105","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.mcn.2007.10.004","volume":"37","author":"LF Gumy","year":"2008","unstructured":"Gumy LF, Bampton ET, Tolkovsky AM. Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol Cell Neurosci. 2008;37(2):298\u2013311. https:\/\/doi.org\/10.1016\/j.mcn.2007.10.004.","journal-title":"Mol Cell Neurosci"},{"key":"1292_CR106","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/B978-0-444-52902-2.00034-5","volume":"115","author":"AM Vincent","year":"2013","unstructured":"Vincent AM, Calabek B, Roberts L, Feldman EL. Biology of diabetic neuropathy. Handb Clin Neurol. 2013;115:591\u2013606. https:\/\/doi.org\/10.1016\/B978-0-444-52902-2.00034-5.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"1292_CR107","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1096\/fj.201700206R","volume":"32","author":"AE Rumora","year":"2018","unstructured":"Rumora AE, Lentz SI, Hinder LM, Jackson SW, Valesano A, Levinson GE, et al. Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. FASEB J. 2018;32(1):195\u2013207. https:\/\/doi.org\/10.1096\/fj.201700206R.","journal-title":"FASEB J"},{"issue":"22","key":"1292_CR108","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1161\/01.CIR.0000103680.61390.16","volume":"108","author":"CM Welzig","year":"2003","unstructured":"Welzig CM, Shin DG, Park HJ, Kim YJ, Saul JP, Galper JB. Lipid Lowering by Pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation. 2003;108(22):2743\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000103680.61390.16.","journal-title":"Circulation"},{"issue":"5","key":"1292_CR109","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/1056-8727(95)00081-x","volume":"10","author":"Y Okuda","year":"1996","unstructured":"Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabetes Complications. 1996;10(5):280\u20137. https:\/\/doi.org\/10.1016\/1056-8727(95)00081-x.","journal-title":"J Diabetes Complications"},{"issue":"4","key":"1292_CR110","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00125-007-0919-2","volume":"51","author":"TM Davis","year":"2008","unstructured":"Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle diabetes study. Diabetologia. 2008;51(4):562\u20136. https:\/\/doi.org\/10.1007\/s00125-007-0919-2.","journal-title":"Diabetologia"},{"issue":"1","key":"1292_CR111","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2337\/dc20-1842","volume":"44","author":"Y Tang","year":"2021","unstructured":"Tang Y, Shah H, Bueno Junior CR, Sun X, Mitri J, Sambataro M, et al. Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD trial. Diabetes Care. 2021;44(1):164\u201373. https:\/\/doi.org\/10.2337\/dc20-1842.","journal-title":"Diabetes Care"},{"issue":"1","key":"1292_CR112","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2337\/dci22-0043","volume":"46","author":"K McDermott","year":"2023","unstructured":"McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023;46(1):209\u201321. https:\/\/doi.org\/10.2337\/dci22-0043.","journal-title":"Diabetes Care"},{"issue":"24","key":"1292_CR113","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367\u201375. https:\/\/doi.org\/10.1056\/NEJMra1615439.","journal-title":"N Engl J Med"},{"issue":"4","key":"1292_CR114","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000001192","volume":"149","author":"KA Gallagher","year":"2024","unstructured":"Gallagher KA, Mills JL, Armstrong DG, Conte MS, Kirsner RS, Minc SD, et al. Current status and principles for the treatment and prevention of diabetic foot ulcers in the cardiovascular patient population: A scientific statement from the American heart association. Circulation. 2024;149(4):e232\u201353. https:\/\/doi.org\/10.1161\/CIR.0000000000001192.","journal-title":"Circulation"},{"issue":"9677","key":"1292_CR115","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","volume":"373","author":"K Rajamani","year":"2009","unstructured":"Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D\u2019Emden MC, et al. Effect of Fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(09)60698-X.","journal-title":"Lancet"},{"issue":"1","key":"1292_CR116","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12933-024-02422-9","volume":"23","author":"EJ Ku","year":"2024","unstructured":"Ku EJ, Kim B, Han K, Lee SH, Kwon HS. Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT. Cardiovasc Diabetol. 2024;23(1):329. https:\/\/doi.org\/10.1186\/s12933-024-02422-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1292_CR117","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS, Austin P, Hernandez G, Lip GYH, et al. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024;67(7):1271\u201382. https:\/\/doi.org\/10.1007\/s00125-024-06132-5.","journal-title":"Diabetologia"},{"key":"1292_CR118","doi-asserted-by":"publisher","first-page":"1065856","DOI":"10.3389\/fendo.2022.1065856","volume":"13","author":"Z Xie","year":"2022","unstructured":"Xie Z, Xiao X. Novel biomarkers and therapeutic approaches for diabetic retinopathy and nephropathy: recent progress and future perspectives. Front Endocrinol (Lausanne). 2022;13:1065856. https:\/\/doi.org\/10.3389\/fendo.2022.1065856.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01292-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:46:09Z","timestamp":1742489169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01292-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"12 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies with human or animal subjects are published and followed ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"39"}}